Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.


Phase N/A Results N/A

Trial Description

This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease, amyotrophic lateral sclerosis, brain injury, Huntington's Disease, multiple sclerosis, Parkinson's Disease, post-stroke, spinal cord injury.

Detailed Description

Laughter therapy (LT) has potential benefits in treating illness. It combines laughter with breathing and body exercises to stimulate laughter, both real and artificial, in a group setting. Laughter therapy may help treating illness by strengthening breathing muscles, improving mood, and providing pain and stress relief. EvergreenHealth has presented laughter therapy classes to patients with Parkinson's disease and Multiple sclerosis and other neurological conditions. The therapy will be led by a certified laughter therapist and mental health professional.



  • Laughter Therapy Other
    Intervention Desc: Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
    ARM 1: Kind: Experimental
    Label: Laughter therapy
    Description: effects of Laughter therapy (LT) on mood, self-efficacy and other wellness measures in people with neurological conditions.

Trial Design

  • Masking: Open Label
  • Purpose: Health Services Research
  • Endpoint: Safety/Efficacy Study
  • Intervention: Single Group Assignment


Type Measure Time Frame Safety Issue
Primary Patient Health Questionnaire (PHQ-9, for depression) Change from Baseline to 8 weeks No
Primary Generalized Anxiety Disorder 7-item scale (GAD-7, for anxiety) Change from Baseline to 8 weeks No
Secondary The General Self-Efficacy Scale (GSE) Change from Baseline to 8 weeks No